PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22093831-8	2011	Over-expression of exogenous Nkx3.2 promoted glycosaminoglycan (GAG) production and inhibited Runx2 mRNA expression and, based on a dual luciferase assay, Runx2 promoter activity.	Glycosaminoglycans	45-62	NK3 homeobox 2	Mus musculus	29-35	
22511961-5	2012	Overexpression of wild-type Nkx3.2 (WT-Nkx3.2) upregulated glycosaminoglycan (GAG) production and expression of type II collagen alpha1 (Col2a1) mRNA, and these effects were evident before WT-Nkx3.2-mediated upregulation of Sox9.	Glycosaminoglycans	59-76	NK3 homeobox 2	Mus musculus	28-34	
22511961-5	2012	Overexpression of wild-type Nkx3.2 (WT-Nkx3.2) upregulated glycosaminoglycan (GAG) production and expression of type II collagen alpha1 (Col2a1) mRNA, and these effects were evident before WT-Nkx3.2-mediated upregulation of Sox9.	Glycosaminoglycans	59-76	NK3 homeobox 2	Mus musculus	39-45	
22511961-5	2012	Overexpression of wild-type Nkx3.2 (WT-Nkx3.2) upregulated glycosaminoglycan (GAG) production and expression of type II collagen alpha1 (Col2a1) mRNA, and these effects were evident before WT-Nkx3.2-mediated upregulation of Sox9.	Glycosaminoglycans	59-76	NK3 homeobox 2	Mus musculus	39-45	
22511961-5	2012	Overexpression of wild-type Nkx3.2 (WT-Nkx3.2) upregulated glycosaminoglycan (GAG) production and expression of type II collagen alpha1 (Col2a1) mRNA, and these effects were evident before WT-Nkx3.2-mediated upregulation of Sox9.	Glycosaminoglycans	78-81	NK3 homeobox 2	Mus musculus	28-34	
22511961-5	2012	Overexpression of wild-type Nkx3.2 (WT-Nkx3.2) upregulated glycosaminoglycan (GAG) production and expression of type II collagen alpha1 (Col2a1) mRNA, and these effects were evident before WT-Nkx3.2-mediated upregulation of Sox9.	Glycosaminoglycans	78-81	NK3 homeobox 2	Mus musculus	39-45	
22511961-5	2012	Overexpression of wild-type Nkx3.2 (WT-Nkx3.2) upregulated glycosaminoglycan (GAG) production and expression of type II collagen alpha1 (Col2a1) mRNA, and these effects were evident before WT-Nkx3.2-mediated upregulation of Sox9.	Glycosaminoglycans	78-81	NK3 homeobox 2	Mus musculus	39-45	
22511961-6	2012	RNAi-mediated inhibition of Nkx3.2 abolished GAG production and expression of Col2a1 mRNA.	Glycosaminoglycans	45-48	NK3 homeobox 2	Mus musculus	28-34	
22511961-8	2012	In addition, WT-Nkx3.2 partially restored downregulation of GAG production, Col2 protein expression, and Col2a1 mRNA expression induced by Sox9 RNAi.	Glycosaminoglycans	60-63	NK3 homeobox 2	Mus musculus	16-22	
22093831-8	2011	Over-expression of exogenous Nkx3.2 promoted glycosaminoglycan (GAG) production and inhibited Runx2 mRNA expression and, based on a dual luciferase assay, Runx2 promoter activity.	Glycosaminoglycans	64-67	NK3 homeobox 2	Mus musculus	29-35	
22093831-9	2011	Interestingly, downregulation of Nkx3.2 using RNAi abolished hypoxia-dependent GAG production and restored Runx2 mRNA expression and promoter activity.	Glycosaminoglycans	79-82	NK3 homeobox 2	Mus musculus	33-39